NY-UPFLEX
20.12.2022 15:01:37 CET | Business Wire | Press release
Upflex, the premier provider of hybrid workspace solutions, is bringing yet another successful year of company growth to a close. This momentum — a testament to flex as a new workplace standard — includes a 400% increase in Upflex’s customer base. Global corporations such as Willis Towers Watson, HH Global, and Schneider Electric, as well as leading tech firms such as Snowflake, Alation and Gympass are among those that have chosen Upflex as their hybrid workspace partner. To serve a fast-growing global demand, Upflex has increased its employee headcount by more than 200% with new hires across 12 countries.
Upflex, which was founded in 2018 by CEO Christophe Garnier and CPO Ginger Dhaliwal, builds technology and solutions to connect companies, space providers, and brokers in one cooperative ecosystem for more manageable, more sustainable flexible work. This year, with flexible workspace options being more important than ever, the company’s platform and flex workspace usage data have been in high demand.
“Since Upflex’s inception, providing a more efficient, flexible, and sustainable way of working has been our core mission,” said Christophe Garnier, CEO and co-founder of Upflex. “In 2022, we have seen that companies across the world are embracing hybrid work, and that they need better solutions for adopting and managing it. We’ve also seen in recent months that enterprise companies are increasingly concerned with cost savings moving toward a potential economic recession, and I’m thrilled that Upflex can be part of the solution for these employers to create new workspace efficiencies that cut real estate costs, so they don’t have to cut their people.”
Earlier this year, Upflex grew its EMEA presence with the acquisition of WorkClub, a UK-based coworking space aggregator, and entered an exclusive, strategic global partnership with WeWork, adding hundreds of WeWork locations to Upflex’s network of thousands of bookable desks, meeting rooms, and private offices around the world. As the sole aggregator of WeWork inventory, Upflex and WeWork clients benefit from enhanced coverage and optionality in workspaces. In May, Upflex announced a $30 million Series A round led by WeWork, with participation from top strategic and venture funds, including Newmark, Cushman & Wakefield, Industry Ventures, Inertia Ventures and GPO Fund.
Other 2022 milestones for Upflex include:
- Being selected as a finalist in the most prestigious awards in proptech: CRETech’s Real Estate Tech Awards;
- Expanding from 74 to 120 countries, including China, Japan, Indonesia, and Brazil, and increasing the company’s presence from 875 to 1,250 cities;
- Expanding Upflex's global workspace network from 4,900 to 10,000 workspace locations and adding 325 operators reaching a total of 1,350 operators;
- Launching a major partnership with brokerage firm Newmark to power Optality, a white-labeled version of the Upflex app. This partnership expands upon Upflex’s impressive roster of brokerage partners, including Colliers.
- Expanding its White Label offering to global flex operators including the UK’s largest flex operator Landmark, to make booking and payment instant and seamless for all their users across nearly 50 locations in nine major UK cities;
- Partnering with Chief Brand Advisory (CBA) in October to launch a reimagined brand strategy, in tandem adding CBA’s Founder, Brad Kay, as an investor and advisor;
- Continuing its partnership with the non-profit Trees for the Future to plant a tree for every desk booked on its platform. So far, Upflex has planted over 20,000 trees, a significant impact on reducing global carbon emissions and supporting its core mission of sustainability.
“Upflex will continue to invest a tremendous amount of resources to advance the development of our best-in-class hybrid work technology,” said Ginger Dhaliwal, CPO and co-founder of Upflex. “As companies look to make more informed real estate decisions, the future of the evolving workplace lies in utilization data. With Upflex’s real-time employee analytics, companies are able to be proactive in their workplace planning as they work to build sustainable strategies that serve their business, their people, and the planet.”
About Upflex:
Upflex (upflex.com) is a workspace intelligence platform bringing together people, places, and data to deliver the right workplace strategies for forward-thinking companies and their employees, from startups to the Fortune 100. Founded in 2018 as a co-working aggregator and booking platform, the company recently raised $30MM in Series A funding, forged an exclusive partnership with WeWork, and is expanding its operations to strengthen its global network. Today, Upflex has evolved beyond an aggregator, connecting companies, space providers and brokers to create an ecosystem of flexible and sustainable workspace experiences. Upflex leverages technology, services, and insights to make finding and managing global workspaces simple, smarter, and more agile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
